Type of information: Loan
Company: Grifols (Spain)
Investors: European Investment Bank (EIB)
Amount: € 85 million
Funding type: loan
- The loan will support Grifols' research on rare and chronic diseases. The spanish group will investigate new indications for plasma-derived protein therapies to treat rare and chronic diseases.
- • On December 5, 2017, the European Investment Bank (EIB) and Grifols signed today a € 85 million loan to support the company’s R+D+i initiatives focused on investigating new indications for plasma-derived protein therapies to treat rare and chronic diseases. The agreement is backed by the European Fund for Strategic Investments (EFSI). The EFSI is the central pillar of the Investment Plan for Europe, commonly known as the “Juncker Plan”. The loan offers several favorable financial conditions, including a fixed interest rate, maturity date in 2027 and a two-year grace period.
- The agreement represents the second EIB loan conceded to Grifols under the umbrella of the Investment Plan for Europe, following the first one signed in 2015 when Grifols became one of the first European companies to receive funding from the Juncker Plan. With this second loan, the company builds on its positive initial experience and consolidates its relationship with the institution, which it highly values as a complementary source of funding for its R+D+i projects.
- As a leading-edge innovator in the global healthcare sector, Grifols channels substantial resources toward both in-house and external R+D+i projects. As of September 30, 2017, the company had allocated € 201.6 million in net investments in R+D+i, denoting a 23.8% increase compared to the same period last year.
Therapeutic area: Rare diseases - Genetic diseases